Back to Search
ROBERT DREICER, M.D.
M.D.
Medical Oncology Physician
NPI: 1871557595IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
0101257805(VA)
Education
UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON
Class of 1983
Research & Publications (20)
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
PMID 19230915·J Urol·2009
3-trial
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
PMID 19536901·Cancer·2009
3-trial
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
PMID 19100579·J Urol·2009
8-other
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
PMID 19276286·Clin Cancer Res·2009
8-other
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
PMID 19127557·Cancer·2009
4-observational
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
PMID 18931824·Invest New Drugs·2009
3-trial
HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases.
PMID 18628098·Am J Clin Pathol·2008
8-other
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
PMID 18824429·Clin Genitourin Cancer·2008
3-trial
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
PMID 18459175·Cancer·2008
3-trial
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PMID 18309951·J Clin Oncol·2008
6-review
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
PMID 18927310·Clin Cancer Res·2008
8-other
A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
PMID 18207194·J Urol·2008
8-other
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
PMID 17997441·J Urol·2008
8-other
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
PMID 17962201·Ann Oncol·2008
8-other
Systems pathology and predicting outcome after radical prostatectomy.
PMID 18711177·J Clin Oncol·2008
8-other
Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
PMID 18483371·Clin Cancer Res·2008
3-trial
Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture?
PMID 18615663·Cancer·2008
8-other
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
PMID 18618496·Cancer·2008
8-other
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
PMID 18626572·Invest New Drugs·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1240 LEE ST
CHARLOTTESVILLE, VA 22908 - Phone
- (434) 924-9333
Quick Facts
- NPI
- 1871557595
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 43
- Publications
- 20
Are you this provider?
Claim Your Profile